Evaluation of an Electro-Disinfection Technology as an Alternative to Chlorination of Municipal Wastewater Effluents

This research evaluated and demonstrated the disinfection efficiency of an electrochemical system for total coliform removal from wastewater effluents after secondary treatment. Four bench scale batch electrochemical cells were assembled and operated in the laboratory: the first electro-disinfection reactor was set with aluminum electrodes, the second with standard 316 stainless steel electrodes, the third one with titanium electrodes, and the fourth one with a standard 316 stainless steel cathode and a titanium anode. During the electro-disinfection process the water sample was placed on the reactor/disinfector to which direct current (DC) was charged. The results showed that total coliform counts in the treated water decreased significantly and that the characteristics of the effluent were highly improved, especially when stainless steel or titanium electrodes were employed. A bactericidal efficiency of 98.7 % or higher was achieved within a contact time of less than 15 min and a current density lower than 7.5 mA/cm2 when stainless steel electrodes were used, and a contact time of less than 5 min and a current density lower than 3.5 mA/cm2 when the stainless steel/titanium cell was utilized. Electrochlorination does not seem to be the predominant disinfective means of the process. Production of other short lived and more powerful killing substances such as H2O2, [O], •OH, and •HO2 provide the strong disinfecting action of the system within a short contact time. The bactericidal efficiency of the process generally increased with the current density and contact time, and the impact of these factors was much larger than that of salinity. The results obtained suggest that this electrochemical treatment is applicable to wastewater effluents. However, further investigation on the optimum operating conditions and a detailed comparative study of energy consumption by the electrochemical treatment system and the conventional methods are needed before constructing an industrial application system in the future. It is also indispensable to find out if halogenated hydrocarbons and other toxic compounds are produced during the process

HIV self-testing in Spain: A valuable testing option for men-who-have-sex-with-men who have never tested for HIV

BACKGROUND: We assessed the capacity of HIV self-testing to promote testing among untested men who have sex with men (MSM) and determined the most benefited subpopulations. METHODS: An online questionnaire was disseminated on several gay websites in Spain from September 2012 to April 2013. We used Poisson regression to estimate factors associated with the intention to use self-testing if already available. Among those who reported intention of use, we assessed several aspects related to the testing and linkage to care process by type of barrier reported: low perceived risk (LR), structural barriers (SB) and fear of testing positive (FTP). RESULTS: Of 2589 never-tested MSM, 83% would have used self-testing if already available. Intention of use was associated with age ≥30 (adj.PR, 95%CI: 1.05, 1.01-1.10), having had protected (adj.PR, 95%CI: 1.15, 1.02-1.30) or unprotected (adj.PR, 95%CI: 1.21, 1.07-1.37) anal intercourse and reporting FTP (adj.PR, 95%CI: 1.12, 1.05-1.20) or SB to access HIV testing (adj.PR, 95%CI: 1.23, 1.19-1.28). Among those who reported intention of using a self-testi, 78.3% declared it their preferred option (83.8% in the SB group; p<0.001), and 56.8% would always use this testing option (60.9% among the SB group; p = 0.001). In the case of obtaining a positive self-test, 69.3% would seek confirmatory testing, 15.3% would self-test again before taking any decision and 13.0% reported not being sure of what they would do. CONCLUSION: HIV self-testing in Spain has the potential of becoming a highly used testing methodology for untested MSM and could represent the gateway to testing especially among older, at risk MSM who report SB or FTP as main barriers to testing.This study was funded by the Ministerio de Sanidad, Servicios Sociales e igualdad (https://www.msssi.gob.es/) (MSSSI EC11-279). Work by JP was also partially supported by "Ayuda Juan de la Cierva-Incorporación" (Grant number IJCI-2015-23261).S

Epidemiología del abuso de alcohol entre la población inmigrante en España

[EN] In recent years, the immigrant population has substantially increased in Spain. However, there is a lack of information in the knowledge of alcohol abuse among Spanish immigrants. We describe the epidemiology of alcohol abuse among foreign-born immigrants versus Spanish natives. We carried out a cross-sectional study that uses data from the European Survey of Health on the General Population of Spain of 2009. A sample of 22,188 subjects was analyzed (of whom, 3,162 were foreign). Proxies of problematic alcohol consumption were the prevalence of excessive average consumption and the prevalence of excessive episodic consumption (binge drinking). Descriptive analysis of the population, determination of area of origin with major alcohol consumption and related factors for each kind of consumption, separating immigrant and native population, were performed. The immigrant profile was heterogeneous, though predominantly aged between 35 and 54, and were living with their family and working. 3.4% of immigrants and 3.2% of natives were considered excessive drinkers; 8.9% and 10%, respectively, reported binge drinking in the last year. Immigrants from Northern and Western Europe, and Latin America, Andean countries had significantly a higher report of frequent alcohol consumption and/or binge drinking compared to native. On the contrary, born in Africa was a protective factor. Unemployment was the most relevant related factor, being more important in the immigrant population. The excessive alcohol consumption in immigrants is dissimilar; the interventions must be adapted to their social situation, environments and areas of origin. [ES] A pesar del gran incremento de la población inmigrante en los últimos años, su uso de alcohol está poco estudiado. Se describe la epidemiología del consumo de riesgo de alcohol en la población inmigrante residente en España, frente a la nativa. Se emplearon datos de 22188 respondientes a la Encuesta Europea de Salud de 2009, de los que 3162 eran extranjeros. Como indicadores de consumo problemático se usó la prevalencia de consumo excesivo promedio y el consumo excesivo episódico. Se realizaron análisis descriptivo de la población, determinación de zonas de procedencia con mayor consumo de alcohol y factores relacionados para cada tipo de consumo separando población inmigrante de autóctona. El perfil sociodemográfico del inmigrante fue heterogéneo, aunque predominantemente de entre 35 y 54 años, que vive en familia y trabaja. Se consideraron bebedores excesivos promedio al 3,4% de los inmigrantes por el 3,2% de los nativos, y bebedores excesivos episódicos en el último año el 8,9% frente al 10%. Los inmigrantes procedentes de Europa del Norte y del Oeste, y América latina, países andinos, fueron aquellos que presentaron mayores razones de prevalencia de bebedores de riesgo que la población nativa. Por el contrario, proceder de África fue un factor protector. De los factores relacionados con un mayor consumo, destaca el desempleo, siendo más relevante en la población inmigrante. El consumo excesivo de alcohol en inmigrantes es muy heterogéneo, debiendo adecuarse las intervenciones sobre el mismo a su situación social, diferentes entornos y áreas de procedencia.The authors thank the National Drug Plan (Plan Nacional sobre Drogas, órdenes SSI 2800/2012 and 131/2013) and the Health Strategic Agency (Agencia Estratégica en Salud (AES), PI13/00183 and PI 11/01396) for their financial help. This project has also received financing from the Active Disorders Network (Red de Trastornos Activos – RTA) (RD12/0028/0018) and from the 2011/059 project. The manuscript was produced with the help of the CD10/00128- Sara Borrell contract.S

Elaboració de la primera Guia de Bones Pràctiques d'Informació Mèdica a la Indústria Farmacèutica Espanyola

Informació mèdica; Indústria farmacèutica; Bones pràctiquesInformación médica; Industria farmacéutica; Buenas prácticasMedical information; Pharmaceutical industry; Good practicesIntroducció. La indústria farmacèutica (IF) és un important proveïdor d'informació i documentació mèdica. La Informació Mèdica (IM) és una activitat necessària per tal que els medicaments i productes sanitaris comercialitzats per les empreses farmacèutiques s'utilitzin de forma segura i eficaç. Per aquest motiu, han de proporcionar informació fiable, precisa, equilibrada i imparcial a professionals de la salut i pacients. El Grup d'IM d'AMIFE es creà el 2014 com a fòrum de debat sobre la situació actual i el futur de la IM, dels seus professionals i dels serveis que proporciona. Objectiu. En no haver-hi legislació específica, el Grup es plantejà la importància de definir i orientar les obligacions i activitats d'IM a la IF. Encara que hi ha algunes guies internacionals, es considerà imprescindible elaborar una guia espanyola de bones pràctiques. Mètode. Coordinat per dos membres del Grup, es convidà tot el Grup a participar en el projecte, tant en la planificació com en la redacció, avaluació d'experts i edició dels capítols. Es va elaborar l'índex i s'assignaren els autors. Cada capítol havia d'incloure una revisió del tema i observacions o conclusions que, consensuades, donarien lloc a recomanacions. Resultats. S'ha redactat, i es publicarà molt aviat, la Guia de Bones Pràctiques d'Informació Mèdica a la Indústria Farmacèutica Espanyola. En 12 capítols es tracta de la importància de la IM, les característiques dels departaments d'IM i els seus professionals, i els procediments normalitzats de treball així com de temes legals, d'ètica, de propietat intel·lectual, de medicina basada en l'evidència i d'avaluació de la qualitat, i es plantegen els reptes futurs. Conclusions. És important disposar d'una Guia de Bones Pràctiques d'IM a la IF. Aquest treball ha permès aprofundir en el tema, redactar la primera guia espanyola i elaborar conclusions i recomanacions així com establir una xarxa col·laborativa entre els professionals d'IM de la IF.Introducción. La industria farmacéutica (IF) es un importante proveedor de información y documentación médica. La Información Médica (IM) es una actividad necesaria para que los medicamentos y productos sanitarios comercializados por las empresas farmacéuticas se utilicen de forma segura y eficaz. Por este motivo, deben proporcionar información fiable, precisa, equilibrada e imparcial a profesionales de la salud y pacientes. El Grupo de IM de AMIFE se creó en 2014 como foro de debate sobre la situación actual y el futuro de la IM, de sus profesionales y de los servicios que proporciona.Introduction. The pharmaceutical industry is a leading provider of medical information and documentation. The Medical Information is a necessary activity so that the medicines and sanitary products marketed by the pharmaceutical companies are used safely and efficiently. For this reason, they must provide reliable, accurate, balanced and unbiased information to healthcare professionals and patients. The AMIFE IM Group was created in 2014 as a forum for debate on the current situation and the future of the IM, its professionals and the services it provide

Large expert-curated database for benchmarking document similarity detection in biomedical literature search

Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions

Background and Aim: The circulating recombinant form 02_AG (CRF02_AG) is the predominant clade among the human immunodeficiency virus type-1 (HIV-1) non-Bs with a prevalence of 5.97% (95% Confidence Interval-CI: 5.41–6.57%) across Spain. Our aim was to estimate the levels of regional clustering for CRF02_AG and the spatiotemporal characteristics of the largest CRF02_AG subepidemic in Spain.Methods: We studied 396 CRF02_AG sequences obtained from HIV-1 diagnosed patients during 2000–2014 from 10 autonomous communities of Spain. Phylogenetic analysis was performed on the 391 CRF02_AG sequences along with all globally sampled CRF02_AG sequences (N = 3,302) as references. Phylodynamic and phylogeographic analysis was performed to the largest CRF02_AG monophyletic cluster by a Bayesian method in BEAST v1.8.0 and by reconstructing ancestral states using the criterion of parsimony in Mesquite v3.4, respectively.Results: The HIV-1 CRF02_AG prevalence differed across Spanish autonomous communities we sampled from (p &lt; 0.001). Phylogenetic analysis revealed that 52.7% of the CRF02_AG sequences formed 56 monophyletic clusters, with a range of 2–79 sequences. The CRF02_AG regional dispersal differed across Spain (p = 0.003), as suggested by monophyletic clustering. For the largest monophyletic cluster (subepidemic) (N = 79), 49.4% of the clustered sequences originated from Madrid, while most sequences (51.9%) had been obtained from men having sex with men (MSM). Molecular clock analysis suggested that the origin (tMRCA) of the CRF02_AG subepidemic was in 2002 (median estimate; 95% Highest Posterior Density-HPD interval: 1999–2004). Additionally, we found significant clustering within the CRF02_AG subepidemic according to the ethnic origin.Conclusion: CRF02_AG has been introduced as a result of multiple introductions in Spain, following regional dispersal in several cases. We showed that CRF02_AG transmissions were mostly due to regional dispersal in Spain. The hot-spot for the largest CRF02_AG regional subepidemic in Spain was in Madrid associated with MSM transmission risk group. The existence of subepidemics suggest that several spillovers occurred from Madrid to other areas. CRF02_AG sequences from Hispanics were clustered in a separate subclade suggesting no linkage between the local and Hispanic subepidemics

Pasados y presente. Estudios para el profesor Ricardo García Cárcel

Ricardo García Cárcel (Requena, 1948) estudió Historia en Valencia bajo el magisterio de Joan Reglà, con quien formó parte del primer profesorado de historia moderna en la Universidad Autónoma de Barcelona. En esta universidad, desde hace prácticamente cincuenta años, ha desarrollado una extraordinaria labor docente y de investigación marcada por un sagaz instinto histórico, que le ha convertido en pionero de casi todo lo que ha estudiado: las Germanías, la historia de la Cataluña moderna, la Inquisición, las culturas del Siglo de Oro, la Leyenda Negra, Felipe II, Felipe V, Austrias y Borbones, la guerra de la Independencia, la historia cultural, los mitos de la historia de España... Muy pocos tienen su capacidad para reflexionar, ordenar, analizar, conceptualizar y proponer una visión amplia y llena de matices sobre el pasado y las interpretaciones historiográficas. A su laboriosidad inimitable se añade una dedicación sin límites en el asesoramiento de alumnos e investigadores e impulsando revistas, dosieres, seminarios o publicaciones colectivas. Una mínima correspondencia a su generosidad lo constituye este volumen a manera de ineludible agradecimiento

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials